Program
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
[U]= Recording will be unavailable to view on-demand
*-Short talk from proffered abstract
Sunday, March 5, 2023
Welcome and Opening Keynote Lecture
Monday, March 6, 2023
Plenary Session 1: Biochemistry, Function, and Structure
Plenary Session 2: Signaling Networks
Plenary Session 3: Site-specific Session
Tuesday, march 7, 2023
Plenary Session 4: Metabolism
Plenary Session 5: RASopathies/RAS Superfamily
Plenary Session 6: Immunotherapy/Immunity
Wednesday, march 8, 2023
Plenary Session 7: Targeting RAS
Plenary Session 8: Resistance Mechanisms and Emerging Clinical Data
Closing Keynote Lecture
sunday, March 5, 2023
Registration
3:30-7:30 p.m.
Welcome and Opening KeynotE Lecture
6-7:30 p.m.
Welcome and Introduction of Keynote Speaker
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Keynote Lecture
Targeting KRAS: Light at the end of the tunnel
Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain
Welcome and Introduction of Rising Star Lecturer
Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York
Rising Star Lecture
Targeting RAS in cancer: opportunities and challenges
Andrew Aguirre, Harvard Medical School, Boston, Massachusetts
Opening Reception
7:30-9:00 p.m.
Monday, march 6, 2023
Continental Breakfast
7-8 a.m.
Plenary Session 1: Biochemistry, Function, and Structure
8-10:15 a.m.
Session Chair: Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Treating mutant KRAS tumors with RAS inhibitors, alone of in combination
Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, New York
Emerging therapeutics shed light on the allosteric regulation of KRAS
Piro Lito, Memorial Sloan Kettering Cancer Center, New York, New York
Uncovering new structural insights into RAS interactions with effectors and regulators
Dhirendra K. Simanshu, Frederick National Laboratory for Cancer Research, Frederick, Maryland
Structural plasticity of KRAS oncogenic mutants – a case of misleading conclusions from GTP analogues*
Alok K. Sharma, Frederick National Laboratory for Cancer Research, Frederick, Maryland
Factors modulating RAF dimerization downstream of RAS*
Jawahar Sudhamsu, Genentech Inc., South San Francisco, California
Break
10:15-10:35 a.m.
Plenary Session 2: Signaling Networks
Session Chair: Deborah K. Morrison, National Cancer Institute, Frederick, Maryland
10:35 A.M.-12:55 P.M.
Targeting the ERK-MYC signaling network for the treatment of KRAS-mutant cancers
Channing J. Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Molecular characterization of acquired resistance to KRASG12C–EGFR inhibition in colorectal cancer
Sandra Misale, Memorial Sloan Kettering Cancer Center, New York, New York
Paradoxical activation of oncogenic signaling as a cancer treatment strategy
René Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Direct covalent inhibitors of mutant K-Ras
Kevan M. Shokat, University of California, San Francisco, California
Lunch on own/Free time
12:55-2:15 p.m.
Plenary Session 3: Tackling RAS Using a Disease-specific Approach
Session Chair: Christin E. Burd, The Ohio State University, Columbus, Ohio
2:15-4:35 p.m.
Allelic specificity: The key to NRAS-mutant melanoma initiation?
Christin E. Burd, The Ohio State University, Columbus, Ohio
K-RAS hyperexchange mutants in colorectal cancer
Kevin M. Haigis, Dana-Farber Cancer Institute, Boston, Massachusetts
Three-dimensional genomic mapping of human pancreatic tissue reveals striking multifocality and genetic heterogeneity in precancerous lesions
Laura D. Wood, Johns Hopkins University School of Medicine, Baltimore, Maryland
Developing combinatorial therapies for KRAS-mutant cancers
Karen M. Cichowski, Brigham and Women’s Hospital, Boston, Massachusetts
Poster Session A/Reception
4:45-7 p.m.
Tuesday, March 7, 2023
Continental Breakfast
7-8 a.m.
Plenary Session 4: Metabolism
Session Chair: Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York
8-10:15 a.m.
Identifying metabolic dependencies in pancreatic cancer
Alec C. Kimmelman, New York University Langone Medical Center, New York, New York
Host autophagy mediates organ wasting and nutrient mobilization for tumor growth [U]
Tor Erik Rusten, Norwegian Radium Hospital, Oslo, Norway
Coordinated transcriptional and catabolic programs support iron dependent adaptation to RAS-MAPK pathway inhibition in pancreatic cancer
Rushika M. Perera, University of California, San Francisco, California
Cooperative anti-tumor effects of combined inhibition of KRASG12C plus autophagy in preclinical models of KRASG12C-driven lung cancer*
Phaedra C. Ghazi, University of Utah, Salt Lake City, Utah
A bimodal mechanism of RAS inactivation by monoubiquitination*
Wout Magits, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium
Break
10:15-10:35 a.m.
Plenary Session 5: RASopathies/RAS Superfamily
Session Chair: Marco Tartaglia, Bambino Gesù Children’s Hospital, Rome, Italy
10:35 a.m.-12:15 p.m.
RASopathies: the other face of RAS signaling upregulation
Marco Tartaglia, Bambino Gesù Children’s Hospital, Rome, Italy
Somatic predisposition to germline mutations in the RTK/RAS/MAPK pathway
Anne Goriely, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
The role of the RAS GTPase RIT1 in RASopathies and cancer*
Pau Castel, New York University School of Medicine, New York, New York
Germline RASopathy mutations provide insights into the differential regulation of RAF family kinases*
Russell Spencer-Smith, National Cancer Institute-Frederick, Frederick, Maryland
lunch on own/free time
12:15-2:15 p.m.
Plenary Session 6: RAS and Tumor Immunity
Session Chair: Julian Downward, The Francis Crick Institute, London, England
2:15-4:30 p.m.
Oncogenic KRAS and the regulation of the pancreatic cancer microenvironment
Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, Michigan
The impact of RAS inhibition on tumor immune evasion
Julian Downward, The Francis Crick Institute, London, England
Immune rewiring of mutant Ras tumors: Mechanisms and translational implications
Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York
Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma*
Rachael K. Baliira, University of Michigan, Ann Arbor, Michigan
TCR1020 specific for KRAS G12V restricted to HLA-A*11:01 exhibits potent and precise antigen specificity for clinical development*
Adham S. Bear, University of Pennsylvania, Philadelphia, Pennsylvania
Poster Session B/Reception
4:45-7 p.m.
wednesday, March 8, 2023
Continental Breakfast
7-8 a.m.
Plenary Session 7: Targeting RAS
Session Chair: David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
8-9:40 a.m.
Challenges and opportunities in treating KRAS mutant tumors [U]
Shiva Malek, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
Selectively targeting KRAS mutant alleles: contribution of both cell autonomous and pro-immunogenic MOAs in an expanded spectrum of human cancers
James G. Christensen, Mirati Therapeutics, San Diego, California
KRAS-targeted PROTAC degraders are broadly efficacious against KRAS-dependent tumor models*
Kathryn Smith, Arvinas Operations, Inc., New Haven, Connecticut
IK-595, a MEK-RAF complex inhibitor, obviates CRAF mediated resistance resulting in superior RAS/MAPK pathway inhibition and anti-tumor activity in RAS/RAF altered cancers*
X. Michelle Zhang, Ikena Oncology, Boston, Massachusetts
BREAK
9:40-10 A.M.
Plenary Session 8: Resistance Mechanisms and Emerging Clinical Data
Session Chair: Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain
10-11:45 A.M.
Title to be announced
Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, Tennessee
Systemic interrogation of KRAS function
William C. Hahn, Dana-Farber Cancer Institute, Boston, Massachusetts
Exploiting altered metabolism as a therapeutic strategy for RAS-driven cancers
Kirsten L. Bryant, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
break
11:45 a.m.-12 p.m.
Closing Keynote Lecture
12-12:50 p.m.
Introduction of Keynote Speaker
Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain
Title to be announced
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
Closing Remarks and Departure
12:50 p.m.
Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York